Chaluvaraju KC

Dr. Chaluvaraju KC


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Journal of Basic and Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
CKChaluvaraju KC
Chaluvaraju KC
MNMs Niranjan
Ms Niranjan
TMTr Manjuthej
Tr Manjuthej
TZTr Zaranappa
Tr Zaranappa
KMKrishnappa Mane
Krishnappa Mane
J Basic Clin Pharma, Official publication of Global Scientific Research Forum

1 July 2011 in Journal of Young Pharmacists
Verified
Journal Article
Open access
CKChaluvaraju KC
Chaluvaraju KC
KBK.I. Bhat
K.I. Bhat
Studies were conducted on the anthelmintic property of about 15(e-h, 1e-1h, 2d-2f and 3e-3h) synthesized aminobenzylated Mannich bases bearing N-methyl piperazine using Indian earthworms Pheritima Posthuma against piperazine citrate as standard reference. Three concentrations of each compound (0.1, 0.2, 0.3% w/v) were studied, which involved the determination of paralysis and death time of the worms. The compound 1g exhibited the most significant anthelmintic activity among all the compounds screened against the worms as compared to standard drug. Keywords: Amides, amino benzylated Mannich bases, anthelmintic property, Pheritima posthuma, piperazine citrate

21 August 2026 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
DVDeepika B V
Deepika B V
KGKiran N Gaikwad
Kiran N Gaikwad
SMSourabh Malabade
Sourabh Malabade
SPSukanya Pote
Sukanya Pote
CKChaluvaraju KC
Chaluvaraju KC
RGRavindra Gaikwad
Ravindra Gaikwad
1. Cancer remains a major global health challenge and the second leading cause of mortality worldwide. According to the World Health Organization, nearly 20 million new cancer cases and about 10 mi...

20 May 2026 in Molbank
Verified
Journal Article
Open access
PDF file
MNMunishama Gowda Yenagunte Narayanaswamy
Munishama Gowda Yenagunte Narayanaswamy
Sujeet KumarSujeet Kumar
Sujeet Kumar
SSSiddamsetty Ramachandra Setty
Siddamsetty Ramachandra Setty
BMBasavaraj Metikurki
Basavaraj Metikurki
CKChaluvaraju KC
Chaluvaraju KC
In the present work, we synthesize 2-(4-allyl-2-methoxyphenoxy)-1-(4-phenylpiperazin-1-yl)ethan-1-one, a semisynthetic derivative of the natural product eugenol. The compound was synthesized via a three-step synthetic pathway involving esterification, hydrolysis, and subsequent coupling with 4-phenylpiperazine, as confirmed by FTIR, 1H NMR, 13C NMR, and mass spectrometric data.

4 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MNMunishama Gowda Yenagunte Narayanaswamy
Munishama Gowda Yenagunte Narayanaswamy
Sujeet KumarSujeet Kumar
Sujeet Kumar
SSS Ramachandra Setty
S Ramachandra Setty
BMBasavaraj Metikurki
Basavaraj Metikurki
CKChaluvaraju KC
Chaluvaraju KC
In the present work, we synthesize 2-(4-allyl-2-methoxyphenoxy)-1-(4-phenylpiperazin-1-yl)ethan-1-one, a semisynthetic de-rivative of the natural product eugenol. The compound was synthesized via a three-step synthetic pathway involving esterification, hydrolysis, and subsequent coupling with 4-phenylpiperazine, as confirmed by FTIR, 1H NMR, 13C NMR, and mass spectrometric data.

3 October 2026 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
HBH. D. Bandhavya
H. D. Bandhavya
CKChaluvaraju KC
Chaluvaraju KC
Rosuvastatin calcium (ROS) inhibits HMG-CoA reductase, thereby slows atherosclerosis progression and prevent cardiovascular disease. Atenolol (ATN) is beta 1-selective adrenergic blocker. It is commonly used to treat hypertension, either alone or in conjunction with other antihypertensive medications. As their combination shows synergistic activity immediate release tablet formulation is developed in the present study. The pre-formulation and post-formualtion studies were conducted and AR2 was determined to be best formulation. pKa value for both the drugs were determined by UV-Spectroscopy. The pKa value was found to be 4.317 for ROS and 9.2027 for ATN.